Correlative Imaging : Lymphoma(TEIN Lecture Series 2022 2nd)

Value of the Information & Strength of the Argument

The lecture provides a comprehensive overview of the use of FDG PET/CT in lymphoma, covering clinical indications, staging systems, response criteria, and recent advances. The argumentation is well-structured, building from basic concepts to more complex topics such as immunotherapy response assessment. The speaker effectively uses clinical examples and images to illustrate key points, such as the Deauville score and pseudo-progression. The value lies in its practical relevance for nuclear medicine physicians and oncologists, offering clear guidance on how to interpret FDG PET findings in lymphoma. The argumentation is solid, grounded in established guidelines and recent literature, though it could benefit from more explicit citations.

Scientific Rigor, Source Quality, Title Accuracy

The lecture demonstrates scientific rigor by referencing established guidelines (NCCN, Lugano, Deauville) and recent developments (LYRIC criteria). However, specific sources are not cited in the video, and the description provides no additional references. The title accurately reflects the content, which is a focused lecture on correlative imaging in lymphoma. The speaker’s expertise and the institutional affiliation lend credibility, but the lack of explicit citations limits the ability to verify claims independently.

The title accurately reflects the content, which focuses on correlative imaging (FDG PET/CT) in lymphoma.

7/10

The lecture is delivered by a professor in nuclear medicine from a reputable institution, covering established guidelines (NCCN, Lugano, Deauville) and recent developments (immunotherapy, CAR-T). The content is accurate and well-structured, but lacks detailed references and is based on the lecturer's expertise rather than a systematic review.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to the lecture and speaker
• 05:00Clinical indications for FDG PET in lymphoma
• 10:00Bone marrow assessment with FDG PET
• 15:00PET-adaptive therapy concept
• 20:00Staging systems: Ann Arbor to Lugano
• 25:00Deauville five-point scale explained
• 30:00Lugano classification and staging examples
• 35:00Response assessment criteria for FDG-avid lymphoma
• 40:00Challenges in immunotherapy: pseudo-progression and immune-related adverse events
• 45:00LYRIC criteria for immunomodulatory therapy response

• NCCN Guidelines for Hodgkin Lymphoma — Referenced as basis for clinical indications of FDG PET in lymphoma.
• Lugano Classification — Introduced as the standard staging and response assessment system incorporating FDG PET.
• Deauville Criteria — Five-point scale used for response assessment in FDG-avid lymphoma.
• LYRIC Criteria — Response criteria for immunomodulatory therapy, addressing pseudo-progression.

• NCCN Guidelines — Consistent with the clinical indications for FDG PET in lymphoma.
• Lugano Classification — The lecture's description of staging aligns with the Lugano classification.
• Deauville Criteria — The five-point scale is accurately described.

• None — No discordant sources identified.